Internal Medicine, Hematology & Oncology · Reno, NV
NPI
1932139136
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5423 Reno Corporate Dr.
Reno, NV, 89511
Phone (775) 329-0873
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.9M
187,703 services
Medicare patients, 2024
804
Average age 75
Drug cost, 2024
$7.3M
1,990 prescriptions
Company payments, 2025
$5,608
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tejvir Singh was code J9271 (injection, pembrolizumab, 1 mg), 15,200 times for 27 patients. In total Tejvir Singh billed 187,703 services in 146 codes, and Medicare paid $3.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 15,200 | 27 | $44.51 | $677K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 12,750 | 12 | $0.88 | $11K |
| J0897 Injection, denosumab, 1 mg | Office | 12,660 | 40 | $20.44 | $259K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 12,148 | 13 | $0.06 | $668 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 12,060 | 17 | $38.94 | $470K |
| J0894 Injection, decitabine, 1 mg | Office | 6,750 | 14 | $1.21 | $8,143 |
| J0185 Injection, aprepitant, 1 mg | Office | 4,550 | 15 | $1.31 | $5,962 |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 2,772 | 12 | $20.20 | $56K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,293 | 75 | $0.09 | $203 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,440 | 60 | $0.72 | $1,030 |
| 85025 Blood Count | Office | 1,417 | 513 | $7.59 | $11K |
| 99214 Office E&M - Established | Office | 1,409 | 536 | $94.54 | $133K |
| 36415 Venipuncture Blood Collection | Office | 1,284 | 494 | $8.62 | $11K |
| 80053 Clinical Chemistry | Office | 746 | 389 | $10.32 | $7,698 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 556 | 17 | $0.07 | $40.58 |
By year: 2022 $3.0M for 148,431 services; 2023 $4.4M for 215,558 services; 2024 $3.9M for 187,703 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,417 | 513 | $7.59 | $11K |
| 36415 Venipuncture Blood Collection | 1,284 | 494 | $8.62 | $11K |
| 80053 Clinical Chemistry | 746 | 389 | $10.32 | $7,698 |
| 83615 Clinical Chemistry | 100 | 64 | $5.92 | $592 |
| 83735 Clinical Chemistry | 69 | 48 | $6.57 | $453 |
| 82728 Clinical Chemistry | 64 | 45 | $13.36 | $855 |
| 84100 Clinical Chemistry | 58 | 35 | $4.65 | $270 |
| 85045 Blood Count | 46 | 34 | $3.91 | $180 |
| 81002 Clinical Chemistry | 39 | 23 | $3.41 | $133 |
| 84443 Clinical Chemistry | 38 | 23 | $16.46 | $625 |
Medicare prescription drug claims, 2024
In 2024, the drug Tejvir Singh prescribed most often to Medicare patients was Anastrozole, with 135 prescriptions and refills. In total Tejvir Singh wrote 1,990 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 135 | 292 | 36 | $2,304 |
| Acyclovir Generic | 80 | 124 | 23 | $1,755 |
| Eliquis Apixaban | 76 | 108 | 14 | $60K |
| Hydroxyurea Generic | 63 | 142 | 13 | $1,995 |
| Prednisone Generic | 60 | 72 | 17 | $398 |
| Letrozole Generic | 51 | 124 | 13 | $1,729 |
| Keytruda Pembrolizumab | 46 | 46 | Under 11 | $498K |
| Alendronate Sodium Generic | 45 | 94 | Under 11 | $233 |
| Abiraterone Acetate Generic | 45 | 45 | Under 11 | $52K |
| Ondansetron Odt Ondansetron | 40 | 41 | 23 | $689 |
| Pomalyst Pomalidomide | 40 | 40 | Under 11 | $942K |
| Diphenhydramine Hcl Generic | 38 | 38 | Under 11 | $87.03 |
| Dexamethasone Generic | 38 | 43 | 16 | $512 |
| Venclexta Venetoclax | 37 | 37 | Under 11 | $266K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 36 | 36 | 19 | $1,198 |
Brand drugs: 693 claims; generic drugs: 1,297 claims; opioid claims: 98.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tejvir Singh $5,608 ($5,608 in general payments such as food, travel and fees) from 29 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $3,747.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 4 | $3,747 |
| Astellas Pharma US Inc 4503.T | 6 | $188 |
| Incyte Corporation INCY | 7 | $151 |
| Janssen Biotech, Inc. JNJ | 6 | $137 |
| Pfizer Inc. PFE | 7 | $130 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $125 |
| ASD Specialty Healthcare, LLC | 1 | $125 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $108 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $90.31 |
| GlaxoSmithKline, LLC. GSK | 3 | $80.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.